Kratom, a substance with effects on opioid receptors, is as easily accessible as everyday products. Derived from a tree native to Southeast Asia, kratom’s leaves have historically been chewed or made into tea for their stimulating effects akin to opioids. In the U.S., the kratom industry has thrived into a billion-dollar market, available online and in countless stores, including gas stations.
Proponents of kratom praise it as a mild stimulant and support for opioid addiction recovery. Supported by figures in government, it remains legal in most states. Contrarily, health experts caution that kratom can cause addiction and fatalities. Dr. Andrew Kolodny of Brandeis University warns of its effects resembling those of known opioids like oxycodone, heroin, and fentanyl. According to the Centers for Disease Control and Prevention, kratom was found in over 5,000 overdose deaths from 2020-2024.
“He was looking for something for energy. A friend of his told him it was safer than Red Bull,” said Wendy Chamberlain about her son Joe.
The deaths of individuals such as Matthew and Joe have been linked solely to mitragynine, kratom’s primary opioid. Families shared their tragic stories with “60 Minutes,” detailing how misinformation led their sons to perceive kratom as benign. Susan Eppard recounted her son’s sudden collapse during a card game, expressing the anguish of losing him.
Toxicologist Justin Brower from NMS Labs stated he has analyzed numerous kratom-related deaths, with many attributed only to kratom. Fatalities have surged “about tenfold” since 2014, reflecting kratom’s growing use in the U.S. The FDA warns against kratom, citing risks of liver toxicity, seizures, and substance use disorder.
Heightened concern surrounds kratom-derived products, prompting the federal government to consider restricting certain kratom-based substances. However, in a recent turn, the Department of Health and Human Services adjusted standards by increasing the permissible amount of a synthetic component, 7-OH, in kratom products. This change stunned health officials like Dr. Marty Makary and Calley Means.
Public records revealed a persistent flow of funds, primarily from the American Kratom Association, for lobbying efforts targeting regulatory bodies and political leaders. Kolodny likened these actions to Purdue Pharma’s historical lobbying for OxyContin. The association insists on distinguishing natural kratom from “dangerous chemically manipulated products.”
Despite the controversies, kratom remains widely available, much to the dismay of grieving families who share their stories in hopes of spreading awareness. “60 Minutes” investigated the ongoing debate, highlighting calls for increased scrutiny and regulation.
